Medical/Pharmaceuticals
Bridge Biotherapeutics and Scripps Research Launch Research Collaboration to Develop Discovery Platform and Novel Covalent Probes Based on Chemical Biology and Chemoproteomics
* Two-year research collaboration to develop new reactive group chemistries targeting non-cysteine amino acids to expand druggable binding sites and identify novel targets in oncology and immunology * Collaborators at Scripps are pioneers in the field of chemical biology and chemistry SEONGNA...
2022-02-08 06:00
2424
IonOpticks enters OEM partnership with Bruker that sets a new standard for mass spectrometry-based research
MELBOURNE, Australia, Feb. 7, 2022 /PRNewswire/ -- Premium manufacturer of chromatography for proteomics applications, IonOpticks, has entered an OEM partnership with the Bruker Corporation (Nasdaq: BRKR), allowing Bruker to expand their portfolio of 4D-Proteomics solutions with the release of th...
2022-02-08 00:01
2630
US FDA Study May Proceed letter for Clarity's Cu-64 SAR-bisPSMA trial in prostate cancer
SYDNEY, Feb. 7, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has received a confirmation from the US Food and Drug Adm...
2022-02-07 22:08
2746
KAZIA THERAPEUTICS TO PRESENT AT BIO CEO CONFERENCE
SYDNEY, Feb. 7, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, DrJames Garner, will be presenting at the BIO CEO Conference, to be held in person and virtually inNew York, NY, from 14-17 Febr...
2022-02-07 21:00
3918
Samsung Biologics receives 2022 CMO Leadership Award in all six categories
INCHEON, South Korea, Feb. 7, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), announced that it has been selected as a winner of the 2022 CMO Leadership Awards presented by Outsourced Pharma and Life Science ...
2022-02-07 20:00
2847
Genesis MedTech Acquires JC Medical, Creates New Structural Heart Franchise
SINGAPORE, Feb. 4, 2022 /PRNewswire/ -- Genesis MedTech Group (Genesis or Group) has completed the acquisition of JC Medical (JCM), a structural heart company that is primarily engaged in the design and development of transcatheter valve replacement products for the minimally invasive treatment ...
2022-02-05 08:00
5079
New Zealand's Medsafe Grants Provisional Approval for Novavax' COVID-19 Vaccine
Nuvaxovid™ is the first protein-based COVID-19 vaccine to receive provisional approval for distribution inNew Zealand GAITHERSBURG, Md., Feb. 4, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for ser...
2022-02-04 06:54
3286
LISCure Biosciences Announces Research Collaboration with The Scripps Research Institute for Immuno-Oncology
SEOUL, South Korea, Feb. 3, 2022 /PRNewswire/ -- LISCure Biosciences ("LISCure") announced that it had reached an agreement with TheScripps Research Institute ("Scripps Research") to collaboratively research on bacteria-mediated immuno-oncology candidates against multiple cancer types. Scripps...
2022-02-03 22:00
2369
Formus Labs Raises $5 Million to Automate Orthopedic Surgery Planning; Partners With Zimmer Biomet to Supercharge Global Launch
Formus combines AI and biomechanics to empower orthopedic surgeons with fully interactive 3D models to optimize the preoperative planning process AUCKLAND, New Zealand, Feb. 3, 2022 /PRNewswire/ -- Formus Labs, the world's first automated 3D planner for joint replacement surgeries, today announce...
2022-02-03 03:00
3565
LANDMARK REDUCE LAP-HF II TRIAL DEMONSTRATES CLINICAL BENEFIT OF CORVIA® ATRIAL SHUNT IN LARGE SEGMENT OF HEART FAILURE PATIENTS
REDUCE LAP-HF II study defines treatable HFpEF patient population for atrial shunt therapy TEWKSBURY, Mass., Feb. 1, 2022 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced results from its REDUCE LAP-HF II randomized cli...
2022-02-01 22:50
2641
Holmusk Enters into Collaboration with Metrocare Services
NEW YORK, Feb. 1, 2022 /PRNewswire/ -- Holmusk, a leading global data science and health technology company building the world's largest real-world evidence (RWE) platform for behavioral health, has signed an agreement with Metrocare Services based inDallas, Texas on the use of real-world data to...
2022-02-01 22:00
2930
Clarity advances to cohort 2 in the SARTATE™ neuroblastoma trial
SYDNEY, Feb. 1, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has completed cohort 1 and advanced to cohort 2 in the64Cu...
2022-02-01 21:58
2211
New Business Partnership Between Otsuka Pharmaceutical and Digital Health VR Technology Developer Jolly Good
TOKYO, Feb. 1, 2022 /PRNewswire/ -- With the aim of building a regional cooperative mental health platform, Jolly Good Inc. (Chuo-ku,Tokyo; CEO: Kensuke Joji) and Otsuka Pharmaceutical Co., Ltd. (Chiyoda-ku, Tokyo; President and Representative Director:Makoto Inoue) have signed an agreement for ...
2022-02-01 21:00
2817
Exopharm and Astellas Institute for Regenerative Medicine (AIRM) Sign Master Collaborative Services Agreement
* Astellas Institute for Regenerative Medicine (AIRM) is a subsidiary of Astellas Pharma Inc., a top 20 global pharmaceutical company * Initial services will seek to validate Exopharm's LEAP, LOAD and EVPS technology platforms to manufacture exosomes for Astellas, firstly at Exopharm's facili...
2022-01-31 19:00
2439
AKESO'S LIGUFALIMAB AND IVONESCIMAB OBTAINED APPROVAL TO INITIATE A PHASE II TRIAL
HONG KONG, Jan. 30, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announces that the Ligufalimab (CD47 monoclonal antibody, research and development code: AK117, the novel immuno-oncology drug independently developed by the Company) and Ivonescimab (PD-1/VEGF bi-specific antibody, research and devel...
2022-01-31 10:14
2749
AKESO DOSES FIRST PATIENT IN THE PHASE III TRIAL OF IVONESCIMAB COMBINED WITH CHEMOTHERAPY IN EGFR-TKI RESISTANT EGFR MUTATION ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
HONG KONG, Jan. 30, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announces that the first patient was dosed in a Phase III registrational clinical trial of the Company's novel immuno-oncology drug, Ivonescimab (PD-1/VEGF bi-specific antibody, AK112), combined with chemotherapy versus placebo combin...
2022-01-31 09:51
2731
HanBio Therapeutics Announces the Completion of a US$40 Million Series A Financing Led by OrbiMed and Hankang Capital
SHANGHAI, Jan. 28, 2022 /PRNewswire/ -- HanBio Therapeutics ("HanBio"), a biotechnology company committed to researching and developing next generation transformative medicines, today announced that it has completed aUS$40 million Series A financing to advance the preclinical and clinical develop...
2022-01-29 11:37
8012
CTB001, Bioheng auto CAR - T Product, received Orphan Drug Designation (ODD) from the U.S. FDA
NANJING, China, Jan. 28, 2022 /PRNewswire/ -- Recently, Nanjing Bioheng Biotech Co.,Ltd. ( hereinafter referred to as Bioheng) announced that its anti-claudin 18.2 autologous CAR-T cell therapy product CTB001 received Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for t...
2022-01-28 22:00
3758
Bon Natural Life Limited Announces FY2021 Earnings Release Date and Webcast
* Earnings to be released before market opens on Monday, January 31, 2022 XI'AN, China, Jan. 28, 2022 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will ...
2022-01-28 22:00
6757
I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs
SHANGHAI and GAITHERSBURG, Md., Jan. 28, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced the signing of a partnership agreement with the Hangzhou Qian...
2022-01-28 21:00
3114
Week's Top Stories
Most Reposted
Visa redefines its role in travel with the global expansion of Visa Destinations
[Picked up by 336 media titles]
2026-06-30 10:00Sustainable Tourism Academy Celebrates 3,000-User Milestone in First Year with ASEAN Expansion and New Language Support
[Picked up by 323 media titles]
2026-06-29 12:41
Agoda rolls out suite of new features focused on real-time updates and smarter trip planning
[Picked up by 321 media titles]
2026-07-01 10:00
On-us Brings Real-Time Smart E-Vouchers to Google Wallet, Giving Marketers a Live Read on Customer Behavior
[Picked up by 319 media titles]
2026-06-30 11:00
Avnet Brings Ecosystem Together to Scale Edge AI in Singapore
[Picked up by 305 media titles]
2026-06-30 09:00Most Read
JINRO, the World's No. 1 Soju Brand, Partners with V of BTS
2026-07-03 08:00
11997
/UPDATE TO VIDEO -- New York Stock Exchange/
2026-07-01 01:36
6637
NYSE Content Update: Mobility Global Marks First Day as Public Company
2026-07-01 21:22
5775
Farmmi, Inc. Announces Launch of Proposed Public Offering
2026-06-27 08:01
5395